Health & Fitness
Mon, January 12, 2009Sun, January 11, 2009Fri, January 9, 2009Thu, January 8, 2009Wed, January 7, 2009Tue, January 6, 2009Mon, January 5, 2009Fri, January 2, 2009Thu, January 1, 2009Wed, December 31, 2008Tue, December 30, 2008Mon, December 29, 2008Wed, December 24, 2008Tue, December 23, 2008Mon, December 22, 2008Sun, December 21, 2008Fri, December 19, 2008Thu, December 18, 2008Abiomed to Present at JP Morgan 27th Annual Healthcare Conference in San Francisco
Published in Health and Fitness on Monday, January 5th 2009 at 5:24 GMT, Last Modified on 2009-01-05 05:24:45 by Market Wire
DANVERS, Mass.--([ BUSINESS WIRE ])--[ Abiomed, Inc. ] (NASDAQ: ABMD) today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 27th Annual JP Morgan Healthcare Conference on Wednesday, January 14, 2009 at 11:30 a.m. ET. The conference will be held at the Westin St. Francis from January 12 – 15, in San Francisco, California.
A live audio webcast of the presentation will be available to all interested parties on Abiomed's website at [ www.abiomed.com ] or at the following link: [ https://www.events.jpmorgan.com ].
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: [ www.abiomed.com ].
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
